LGVNLongeveron Inc.

Nasdaq longeveron.com


$ 4.40 $ 0.50 (12.85 %)    

Friday, 12-Jul-2024 15:59:31 EDT
QQQ $ 494.79 $ 2.89 (0.59 %)
DIA $ 400.37 $ 2.69 (0.68 %)
SPY $ 559.91 $ 3.51 (0.63 %)
TLT $ 93.88 $ 0.40 (0.43 %)
GLD $ 223.10 $ -0.14 (-0.06 %)
$ 4.39
$ 3.91
$ 0.00 x 0
$ 0.00 x 0
$ 3.86 - $ 4.61
$ 0.77 - $ 37.50
7,669,081
na
27.87M
$ 0.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-14-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-11-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-is-longeveron-stock-soaring-on-wednesday

Longeveron shares surged after FDA granted RMAT designation to Lomecel-B for mild Alzheimer's Disease. This designation, th...

Core News & Articles
Market-Moving News for July 10th
07/10/2024 12:29:54

VVPR: 119% | VivoPower Secures Amendment And Extension To $34M Shareholder Loan Financing Agreement Following Negotiations With...

 longeveron-announces-us-fda-grants-lomecel-b-regenerative-medicine-advanced-therapy-rmat-designation-for-treatment-of-mild-alzheimers-disease

Lomecel-B is a proprietary, scalable, allogeneic cellular investigational therapy being evaluated across multiple indications, ...

 whats-going-on-with-longeveron-stock

Longeveron shares are trading higher Thursday, and the stock is up more than 200% this week. Here's a look at what's go...